RxDoctor Payments Data

Katherine Tuttle, APRN

Family · Gering, NENPI 1821574807

Payments from drug & device makers

$412in general payments, 2019–2025

Across 21 payments — averaging $19.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$90
  • Merck$89
  • Novo Nordisk$51
  • Xeris Pharmaceuticals, Inc.$44
  • Mylan Specialty L.p.$26
  • Abbott$24
  • plus $88 from 5 others
$6,422in research payments, 2019–2025

Across 14 payments — averaging $458.71 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Novo Nordisk AS$6K

What the payments were for

  • Food & beverage$412100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$412 in reported general payments places this provider in the 60th percentile of 809 family providers in Nebraska.

See all family providers in Nebraska

Medicare billing

Part B allowed, 2024
$7,915
Medicare patients
71
Services billed
920

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala39$161,200
OdefseyEmtricitab/Rilpiviri/Tenof Ala32$111,096
DelstrigoDoravirine/Lamivu/Tenofov Diso16$43,102
TriumeqAbacavir/Dolutegravir/Lamivudi11$40,560
RexultiBrexpiprazole15$28,415
OzempicSemaglutide31$27,876
TrulicityDulaglutide16$18,345
EliquisApixaban30$15,644
MounjaroTirzepatide12$14,332
LinzessLinaclotide18$8,975
Advair HfaFluticasone Propion/Salmeterol17$6,128
Humalog Kwikpen U-100Insulin Lispro13$3,764
Albuterol Sulfate HfaAlbuterol Sulfate41$1,621
Varenicline Tartrate11$1,463
Atorvastatin Calcium102$1,098

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy$90$161,20039 claims
MerckDelstrigo$89$43,10216 claims
Viiv Healthcare CompanyTriumeq$24$40,56011 claims
Otsuka America Pharmaceutical, Inc.Rexulti$13$28,41515 claims
Novo NordiskOzempic$51$27,87631 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 809 family providers in Nebraska.

Other family in Gering

See the full list for Nebraska

Where these figures come from

Is this you, or does something look wrong? →